Journal of Anesthesia

, Volume 32, Issue 6, pp 813–821 | Cite as

Effectiveness of preanesthetic administration of gabapentin on sedative action during intravenous sedation with propofol

  • Rumiko Hosokawa
  • Shinichi ItoEmail author
  • Jun Hirokawa
  • Yu Oshima
  • Takeshi Yokoyama
Original Article



There are no sufficient evidences for the sedative effect of gabapentin during anesthesia, especially intravenous sedation (IVS). The purpose of this study was to evaluate the sedative effect of gabapentin as preanesthetic medication during the IVS with propofol.


10 volunteer subjects joined this study. They underwent propofol IVS three times on separate days. On the first day, the IVS without gabapentin was performed as a control. On the second and the third day, gabapentin 200 mg and 400 mg were administered before the IVS, respectively. The target blood concentration (CT) of propofol was gradually increased, and the bispectral index (BIS) value and Ramsay sedation score (RSS) were evaluated at each propofol CT. Postanesthetic complications and influences on vital signs were also evaluated.


Compared to the control group, the propofol CTs in the gabapentin 400 mg group significantly reduced at the BIS values of 60 and 70 (p = 0.031 and p = 0.043, respectively), and at RSS 3, 4, 5 and 6 (p = 0.040, p = 0.004, p = 0.001 and p = 0.004, respectively). There was no significant difference in propofol CTs between the control group and the gabapentin 200 mg group. There were no abnormality and no deterioration in circulation and respiration in all groups. There were no significant increases in complications with the administration of gabapentin.


The oral administration of 400 mg dose of gabapentin reduced the propofol CTs for achieving an adequate sedation level on IVS.


Gabapentin Hypnotics and sedatives Propofol Consciousness monitors 



This work was supported in part by the Academic Enrichment Fund allotted to the Department of Dental Anesthesiology, Faculty of Dental Science, Kyushu University and by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (24593058).


  1. 1.
    Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem. 1996;271:5768–76.CrossRefGoogle Scholar
  2. 2.
    Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233–49.CrossRefGoogle Scholar
  3. 3.
    Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain. Palliat Med. 2004;18:5–11.CrossRefGoogle Scholar
  4. 4.
    Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016;4:e00205.CrossRefGoogle Scholar
  5. 5.
    Mellick GA, Mellicy LB, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manag. 1995;10:265–6.CrossRefGoogle Scholar
  6. 6.
    Arumugam S, Lau CS, Chamberlain RS. Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. J Pain Res. 2016;12:631–40.Google Scholar
  7. 7.
    Mishra R, Tripathi M, Chandola HC. Comparative clinical study of gabapentin and pregabalin for postoperative analgesia in laparoscopic cholecystectomy. Anesth Essays Res. 2016;10:201–6.CrossRefGoogle Scholar
  8. 8.
    Turan A, Karamanlioğlu B, Memiş D, Hamamcioglu MK, Tükenmez B, Pamukçu Z, Kurt I. Analgesic effects of gabapentin after spinal surgery. Anesthesiology. 2004;100:935–8.CrossRefGoogle Scholar
  9. 9.
    Bharti N, Bala I, Narayan V, Singh G. Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. Acta Anaesthesiol Taiwan. 2013;51:10–3.CrossRefGoogle Scholar
  10. 10.
    Grant MC, Lee H, Page AJ, Hobson D, Wick E, Wu CL. The effect of preoperative gabapentin on postoperative nausea and vomiting: a meta-analysis. Anesth Analg. 2016;122:976–85.CrossRefGoogle Scholar
  11. 11.
    Kong VKF, Irwin MG. Gabapentin: a multimodal perioperative drug? Br J Anaesth. 2007;99:775–86.CrossRefGoogle Scholar
  12. 12.
    Majumdar S, Das A, Das H, Bandyopadhyay S, Hajra BK, Mukherjee D. Comparative evaluation of oral gabapentin versus clonidine as premedication on preoperative sedation and laryngoscopic stress response attenuation for the patients undergoing general anesthesia. Perspect Clin Res. 2015;6:211–6.CrossRefGoogle Scholar
  13. 13.
    Kim YS, Chang HK, Lee JW, Sung YH, Kim SE, Shin MS, Yi JW, Park JH, Kim H, Kim CJ. Protective effect of gabapentin on N-methyl-d-aspartate-induced excitotoxicity in rat hippocampal CA1 neurons. J Pharmacol Sci. 2009;109:144–7.CrossRefGoogle Scholar
  14. 14.
    Todd RD, McDavid SM, Brindley RL, Jewell ML, Currie KP. Gabapentin inhibits catecholamine release from adrenal chromaffin cells. Anesthesiology. 2012;116:1013–24.CrossRefGoogle Scholar
  15. 15.
    Karube N, Ito S, Sako S, Hirokawa J, Yokoyama T. Sedative effects of oral pregabalin premedication on intravenous sedation using propofol target-controlled infusion. J Anesth. 2017;31:586–92.CrossRefGoogle Scholar
  16. 16.
    Olson DM, Chioffi SM, Macy GE, Meek LG, Cook HA. Potential benefits of bispectral index monitoring in critical care. A case study. Crit Care Nurse. 2003;23:45–52.PubMedGoogle Scholar
  17. 17.
    Ramsay MAE, Savege TM, Simpson BRJ, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J. 1974;2:656–9.CrossRefGoogle Scholar
  18. 18.
    Sneyd JR, Rigby-Jones AE, Cross M, Tominaga H, Shimizu S, Ohkura T, Grimsehl K. First human administration of MR04A3: a novel water-soluble nonbenzodiazepine sedative. Anesthesiology. 2012;116:385–95.CrossRefGoogle Scholar
  19. 19.
    De Oliveira GS Jr, Ahmad S, Fitzgerald PC, McCarthy RJ. Detection of hypoventilation during deep sedation in patients undergoing ambulatory gynaecological hysteroscopy: a comparison between transcutaneous and nasal end-tidal carbon dioxide measurements. Br J Anaesth. 2010;104:774–8.CrossRefGoogle Scholar
  20. 20.
    Åkerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;52:29–37.CrossRefGoogle Scholar
  21. 21.
    Kaida K, Takahashi M, Akerstedt T, Nakata A, Otsuka Y, Haratani T, Fukasawa K. Validation of the Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol. 2006;117:1574–81.CrossRefGoogle Scholar
  22. 22.
    Miley A, Kecklund G, Åkerstedt T. Comparing two versions of the Karolinska Sleepiness Scale (KSS). Sleep Biol Rhythms. 2016;14:257–60.CrossRefGoogle Scholar
  23. 23.
    Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46(3):409–27.CrossRefGoogle Scholar
  24. 24.
    Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure. 2008;17:405–21.CrossRefGoogle Scholar
  25. 25.
    Panousis P, Heller AR, Burghardt M, Bley MJ, Koch T. The effects of electromyographic activity on the accuracy of the Narcotrend® monitor compared with the Bispectral Index during combined anaesthesia. Anaesthesia. 2007;62:868–74.CrossRefGoogle Scholar
  26. 26.
    Matsuzaki S, Tanaka H. The feasibility of bispectral index monitoring for intravenous sedation during dental treatment. Anesth Prog. 2004;51:52–5.PubMedPubMedCentralGoogle Scholar
  27. 27.
    LeBlanc JM, Dasta JF, Pruchnicki MC, Gerlach A, Cook C. Bispectral index values, sedation-agitation scores, and plasma Lorazepam concentrations in critically ill surgical patients. Am J Crit Care. 2012;21:99–105.CrossRefGoogle Scholar
  28. 28.
    Taffe P, Sicard N, Pittet V, Pichard S, Burnand B. The occurrence of intra-operative hypotension varies between hospitals: observational analysis of more than 147,000 anaesthesia. Acta Anaesthesiol Scand. 2009;53:995–1005.CrossRefGoogle Scholar
  29. 29.
    Ohtsuka Y. New antiepileptic drugs: characteristics and clinical applications (in Japanese with English abstract). Nihon Rinsho. 2014;72:931–8.PubMedGoogle Scholar
  30. 30.
    Ayatollahi V, Mirshamsi P, Behdad S, Amirdosara M, Vaziribozorg S. Effect of oral gabapentin on haemodynamic variables during microlaryngoscopic surgery. Anaesthesiol Intensive Ther. 2014;46:17–22.CrossRefGoogle Scholar
  31. 31.
    Ali AR, El Gohary M, Ashmawi HSE-D, El-Kerdawy HM, Essa HH. Efficacy of preoperative oral gabapentin in attenuation of neuro-endocrine response to laryngoscopy and endotracheal intubation. J Med Sci. 2009;9:24–9.CrossRefGoogle Scholar
  32. 32.
    Memiş D, Turan A, Karamanlioğlu B, Seker S, Türe M. Gabapentin reduces cardiovascular responses to laryngoscopy and tracheal intubation. Eur J Anaesthesiol. 2006;23:686–90.CrossRefGoogle Scholar
  33. 33.
    Hug CC, McLeskey CH, Nahrwold ML, Roizen MF, Stanley TH, Thisted RA, Walawander CA, White PF, Apfelbaum JL, Grasela TH. Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg. 1993;77:21–9.Google Scholar
  34. 34.
    Robinson BJ, Ebert TJ, O’Brien TJ, Colinco MD, Muzi M. Mechanisms whereby propofol mediates peripheral vasodilation in humans. Sympathoinhibition or direct vascular relaxation? Anesthesiology. 1997;86:64–72.CrossRefGoogle Scholar
  35. 35.
    Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32:601–10.CrossRefGoogle Scholar
  36. 36.
    May TW, Rambeck B, Neb R, Jurgens U. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2007;29:789–94.CrossRefGoogle Scholar
  37. 37.
    Armijo JA, Pena MA, Adin J, Vega-Gil N. Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis. Therap Drug Monit. 2004;26:633–7.CrossRefGoogle Scholar
  38. 38.
    Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57:451–62.CrossRefGoogle Scholar
  39. 39.
    Gajraj NM. Pregabalin for pain management. Pain Pract. 2005;5:95–102.CrossRefGoogle Scholar
  40. 40.
    Wang L, Dong Y, Zhang J, Tan H. The efficacy of gabapentin in reducing pain intensity and postoperative nausea and vomiting following laparoscopic cholecystectomy: a meta-analysis. Medicine (Baltimore). 2017;96:e8007.CrossRefGoogle Scholar
  41. 41.
    Li XD, Han C, Yu WL. Is gabapentin effective and safe in open hysterectomy? A PRISMA compliant meta-analysis of randomized controlled trials. J Clin Anesth. 2017;41:76–83.CrossRefGoogle Scholar
  42. 42.
    Doleman B, Heinink TP, Read DJ, Faleiro RJ, Lund JN, Williams JP. A systematic review and meta-regression analysis of prophylactic gabapentin for postoperative pain. Anaesthesia. 2015;70:1186–204.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2018

Authors and Affiliations

  1. 1.Department of Dental Anesthesiology, Faculty of Dental ScienceKyushu UniversityFukuokaJapan

Personalised recommendations